- Home
- LFT vs OBIO Comparison
LFT vs OBIO Comparison
Compare LFT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- OBIO
- Stock Information
- Founded
- LFT 2012
- OBIO 2017
- Country
- LFT United States
- OBIO United States
- Employees
- LFT N/A
- OBIO N/A
- Industry
- LFT Real Estate Investment Trusts
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- LFT Real Estate
- OBIO Health Care
- Exchange
- LFT Nasdaq
- OBIO Nasdaq
- Market Cap
- LFT 109.9M
- OBIO 118.8M
- IPO Year
- LFT N/A
- OBIO N/A
- Fundamental
- Price
- LFT $2.23
- OBIO $2.55
- Analyst Decision
- LFT Hold
- OBIO Strong Buy
- Analyst Count
- LFT 2
- OBIO 4
- Target Price
- LFT N/A
- OBIO $14.67
- AVG Volume (30 Days)
- LFT 157.0K
- OBIO 451.7K
- Earning Date
- LFT 08-08-2025
- OBIO 08-12-2025
- Dividend Yield
- LFT 11.21%
- OBIO N/A
- EPS Growth
- LFT N/A
- OBIO N/A
- EPS
- LFT 0.18
- OBIO N/A
- Revenue
- LFT $25,803,999.00
- OBIO $2,944,000.00
- Revenue This Year
- LFT $139.76
- OBIO $19.83
- Revenue Next Year
- LFT N/A
- OBIO $12.53
- P/E Ratio
- LFT $12.39
- OBIO N/A
- Revenue Growth
- LFT N/A
- OBIO 41.61
- 52 Week Low
- LFT $2.05
- OBIO $2.37
- 52 Week High
- LFT $2.84
- OBIO $7.04
- Technical
- Relative Strength Index (RSI)
- LFT 52.16
- OBIO 42.61
- Support Level
- LFT $2.09
- OBIO $2.50
- Resistance Level
- LFT $2.33
- OBIO $2.75
- Average True Range (ATR)
- LFT 0.08
- OBIO 0.14
- MACD
- LFT 0.00
- OBIO -0.01
- Stochastic Oscillator
- LFT 60.00
- OBIO 42.50
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.